Published on September 8, 2023, by Barbora Mae Vicha

Stimvia Selected as Top Startup to Exhibit at TechCrunch Disrupt 2023

In a monumental achievement, Stimvia, a pioneering company in the field of neuromodulation, has been chosen to exhibit at TechCrunch Disrupt 2023 as part of Start-up Battlefield 200—the world's premier start-up competition. This prestigious recognition comes as a testament to Stimvia's ground-breaking work in the realm of non-invasive deep brain neuromodulation and its mission to enhance patients' quality of life.

TechCrunch Disrupt 2023: A Gathering of Innovation


TechCrunch's Start-up Battlefield 200 is the pinnacle of start-up competitions, bringing together 200 start-ups from diverse industries worldwide. These companies undergo rigorous training, gain access to masterclasses, private receptions, and engage in investor meet and greets.

Some of the most iconic companies, such as Vurb, Trello, Mint, Dropbox, Yammer, Tripit, Redbeacon, Qwiki, Getaround, and Soluto, have emerged from this platform.

TechCrunch Disrupt remains the authority on debuting revolutionary start-ups, introducing game-changing



technologies, and facilitating discussions among the tech industry's top innovators. This year, disrupt gathers entrepreneurs, investors, hackers, and tech enthusiasts virtually and in-person, offering a platform for interviews, demos, Start-up Battlefield 200, networking, and more.



This year's TechCrunch Disrupt 2023 will take place from Tuesday, September 19 to Thursday, September 21 at the Moscone Centre in San Francisco. Just like in previous years, this year's edition holds the promise of success.

Revolutionising Medicine with Non-Invasive Deep Brain Neuromodulation

Stimvia is at the forefront of medical innovation with its revolutionary non-invasive, Al-driven deep brain neuromodulation device. This cutting-edge technology has the potential to transform the lives of countless patients suffering from various CNS disorders, including Overactive Bladder. By hacking into the brain's neural circuits, Stimvia's device offers hope for a huge number of patients with unmet medical needs.



Hundreds of Lives Impacted, 100 Patents, 3 Clinical Studies, \$6 Million Raised

Stimvia's commitment to innovation is underscored by its track record of helping hundreds of patients regain control over their lives. With an impressive portfolio of 100 patents and 3 prospective clinical studies the company stands as a beacon of innovation in the healthcare sector. Moreover, Stimvia's dedication has been recognized by investors who have contributed \$6 million in funding, further fuelling their mission to make a difference.

A Spot Among the Top 200 Startups

Out of thousands of applicants, Stimvia secured its place among the 200 start-ups selected to pitch in front of investors and TechCrunch editors at this year's TechCrunch Disrupt. These start-ups span various industries, from artificial intelligence and software as a service to fintech, security, sustainability, and space exploration.

Seeking Active Partners to Transform Healthcare

Stimvia is not merely seeking funding; they are actively seeking partners who share their vision of revolutionising healthcare. As they prepare to bring Stimvia to the US market, they invite individuals and organisations keen on transforming healthcare to meet them at TechCrunch Disrupt 2023. You can find team Stimvia at Stand E8 or reach out to them <u>here</u>.

As Stimvia prepares to take the stage at TechCrunch Disrupt 2023, we eagerly anticipate the unveiling of their pioneering technology and the impact it will have on the future of healthcare. Stay tuned for updates as we witness the birth of a potential game-changer in the world of neuromodulation. For more information on TechCrunch Disrupt 2023 and Startup Battlefield 200, visit the conference's <u>website here</u>.